Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life

De Hert, 2016, Antipsychotic treatment, prolactin, and breast tumorigenesis, Psychiatr Danub, 28, 243 Sim, 2005, Changing demography of prostate cancer in Asia, Eur J Cancer, 41, 834, 10.1016/j.ejca.2004.12.033 Shao, 2012, Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration, Cancer Lett, 315, 170, 10.1016/j.canlet.2011.09.035 Baade, 2013, Epidemiology of prostate cancer in the Asia-Pacific region, Prostate Int, 1, 47, 10.12954/PI.12014 Van Dong, 2014, Epidemiology and prevention of prostate cancer in Vietnam, Asian Pac J Cancer Prev, 15, 9747, 10.7314/APJCP.2014.15.22.9747 Chen, 2017, Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts: Data from the PBCG and CPCC, J Urol, 197, 90 Akaza, 2017, Prostate cancer trends in Asia, World J Urol, 35, 859, 10.1007/s00345-016-1939-7 Akaza, 2016, Asia prostate cancer study (A-CaP Study) launch symposium, Prostate Int, 4, 88, 10.1016/j.prnil.2016.03.001 Torvinen, 2016, Use of Patient Assessed Health-Related Quality of Life Instruments in Prostate Cancer Research: A Systematic Review of the Literature 2002-15, Int J Technol Assess Health Care, 32, 97, 10.1017/S0266462316000118 Cooperberg, 2004, Patterns of practice in the United States: insights from CaPSURE on prostate cancer management, Curr Urol Rep, 5, 166, 10.1007/s11934-004-0033-7 Gandaglia, 2016, Prostate Cancer Registries: Current Status and Future Directions, Eur Urol, 69, 998, 10.1016/j.eururo.2015.05.046 Evans, 2013, The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer, BJU Int, 111, E158, 10.1111/j.1464-410X.2012.11530.x Ruseckaite, 2016, Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset, BMC Res Notes, 9, 37, 10.1186/s13104-016-1855-3 Ritch, 2016, Advances in the management of castration resistant prostate cancer, BMJ, 355, i4405, 10.1136/bmj.i4405 Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7 Loriot, 2015, Lancet Oncol, 16, 509, 10.1016/S1470-2045(15)70113-0 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Corfield, 2016, Understanding the role of new systemic agents in the treatment of prostate cancer, BJU Int, 118, 8, 10.1111/bju.13633 Ministry of Health and Welfare, 2013 Halbreich, 2003, Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects, Psychoneuroendocrinology, 28, 53, 10.1016/S0306-4530(02)00112-9 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 EuroQol, 1990, EuroQol--a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 Esper, 1997, Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument, Urology, 50, 920, 10.1016/S0090-4295(97)00459-7 Fizazi, 2014, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, Lancet Oncol, 15, 1147, 10.1016/S1470-2045(14)70303-1 Logothetis, 2012, Lancet Oncol, 13, 1210, 10.1016/S1470-2045(12)70473-4 Ministry of the Interior. 2015 Statistical Yearbook of Interior. Population. Available at http://sowf.moi.gov.tw/stat/year/elist.htm#2 (accessed 23 April 2017). The World Bank. Data & Statistics. Country Groups. http://econ.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20421402∼menuPK:64133156∼pagePK:64133150∼piPK:64133175∼theSitePK:239419,00.html. Accessed 11 Nov 2016. Dalton, 2006, Cancer risk among users of neuroleptic medication: a population-based cohort study, Br J Cancer, 95, 934, 10.1038/sj.bjc.6603259